Quantcast

Latest CHOP Stories

2009-12-05 10:00:00

NEW ORLEANS, Dec. 5 /PRNewswire-USNewswire/ -- There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care. Research presented today at the 51st Annual Meeting of the American Society of Hematology explores optimal induction therapies for managing multiple myeloma, the importance of advance care...

2009-10-22 00:30:00

SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients. Highlights from the presentation...

2009-05-19 10:00:00

Updated Safety data presented at BIO International Convention in Atlanta ATLANTA, May 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) for whom anthracycline-related drugs are typically not to be used due to the increased risk of cardiac failure. As noted...

2009-05-18 12:21:00

ORLANDO, Fla., May 18 /PRNewswire-USNewswire/ -- When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG). At the annual meeting of the American Society of Clinical Oncology (ASCO), researchers say that adding the targeted therapy epratuzumab to a regimen known as R-CHOP...

2009-05-15 09:40:04

When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG).At the annual meeting of the American Society of Clinical Oncology (ASCO), researchers say that adding the targeted therapy epratuzumab to a regimen known as R-CHOP resulted in an overall 12-month survival of 88 percent...

2008-09-23 09:01:09

Genmab, an international biotechnology company, has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma patients in the Phase II study of ofatumumab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone. Patients in this open label study will be randomized into two dose groups of 28 patients each and will receive a total of six infusions of ofatumumab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)....

2008-09-22 09:00:58

COPENHAGEN, September 22 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of 56 previously untreated follicular non-Hodgkin's lymphoma (NHL) patients in the Phase II study of ofatumumab (HuMax-CD20(R)) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). "We are happy to finish enrolment in this first study with ofatumumab in front line follicular NHL patients," said Lisa N. Drakeman, Ph.D., Chief Executive Officer...

2006-12-09 12:00:12

ORLANDO, Fla., Dec. 9 /PRNewswire/ -- Chemotherapy, the most common type of treatment for cancer patients, can cause troublesome side effects, such as nausea and vomiting, hair loss, fatigue, and life-threatening toxicities. An important area of progress has been the development of minimally toxic non- chemotherapy agents that add to the effectiveness of chemotherapy. Three studies being presented today at the 48th Annual Meeting of the American Society of Hematology (ASH(TM)) highlight...

2005-11-02 13:54:54

NEW YORK (Reuters Health) - New treatments incorporating immunotherapy - strategies that boost the immune system -- have significantly improved overall survival of patients with a blood cancer called follicular lymphoma, according to a new report. Emerging data suggest that for patients with follicular lymphoma "initial treatment choices may matter," Dr. Richard I. Fisher from University of Rochester in New York told Reuters Health. Fisher and colleagues compared outcomes of...

2005-10-20 14:32:58

New treatment advances for patients with follicular lymphoma, previously considered an incurable cancer, have reduced deaths in the first four years by 70 percent. A newly published study recommends that doctors carefully choose their patients' initial therapies because there are significant differences in overall survival rates, according to researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center. Scientists compared outcomes for 960 patients treated with...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related